article thumbnail

Top 10 Pharma and Biotech M&As in the Past Decade

XTalks

Blockbuster products like Botox (botulinum toxin) and Restasis (cyclosporine) provided Actavis with high-margin, branded revenue streams that complemented its existing generic drug business. Following the merger, Actavis rebranded itself as Allergan, leveraging the strong recognition of Allergans brand.

Marketing 104
article thumbnail

AbbVie to Present Data From Its Migraine Portfolio at the.

The Pharma Data

–Results from a post-hoc analysis of the Phase 3 PREEMPT trials evaluate the use of BOTOX® (onabotulinumtoxinA) for chronic migraine –These data further demonstrate AbbVie’s commitment to harnessing and sharing innovative science and working to advance treatment options for people with migraine across the migraine spectrum.

Botox 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

pharmaphorum

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

Sales 96
article thumbnail

Novartis’ Aimovig tops topiramate in migraine face-off

pharmaphorum

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial.

Botox 95
article thumbnail

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

pharmaphorum

The decision means that with two CGRP antibodies now cleared for migraine prevention, the first drug in the class to be approved in Europe – Novartis’ Aimovig (erenumab) – has fallen further behind its rivals in getting access to the UK market.

Sales 94
article thumbnail

Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting

The Pharma Data

” Researchers will present data from several studies on migraine, including new findings on atogepant, AbbVie’s investigational preventive treatment of migraine in adults who meet criteria for episodic migraine as well as results evaluating the efficacy and safety of BOTOX ® (onabotulinumtoxinA) and UBRELVY ® (ubrogepant).

Botox 52
article thumbnail

AbbVie Reports Second-Quarter 2021 Financial Results

The Pharma Data

Global Botox Therapeutic net revenues were $603 million, an increase of over 100.0 Global Botox Cosmetic net revenues were $584 million, an increase of over 100.0 AbbVie also presented real-world data on the role of Botox in combination with CGRP mAbs for Chronic Migraine prevention. percent on a reported basis, or 29.6

Botox 52